Telesis Bio Announces First Commercial Shipment of BioXp NGS Library Prep Kit - Seite 2
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.
About Novel Biotechnology Inc.
Novel Biotechnology Inc. is on a mission to develop disruptive platforms that address unmet needs in the life sciences and pharmaceutical domains. Their focus is on developing new solutions for manufacturing plasmid DNA, a critical starting material for gene therapy, cell engineering, mRNA therapy and vaccine applications. They are developing a platform that is safe, scalable, adaptable to different plasmid backbones and payloads, has improved product quality, and is many times more productive than existing systems. Through their services business, they are currently offering plasmid DNA manufacturing services to a growing base of customers.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs
and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding
Telesis Bio’s future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions
that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described
in the section entitled Risk Factors and elsewhere in our Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on May 12, 2023. These
forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.
Lesen Sie auch
Contact:
Jen Carroll
Vice President of Investor Relations
jen.carroll@telesisbio.com